Narrator: Despite their success, each knows that if they revert back to old habits, the weight could easily return
Get baseline bloodwork including fasting glucose, HbA1c, lipid panel, B12, thyroid function, liver enzymes, and kidney function
This condition commonly follows major physiological stressors, including rapid weight loss, caloric restriction, and nutritional deficiencies
Developer: Eli Lilly and Company Classification: Triple Agonist (GIP/GLP-1/Glucagon receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials Expected FDA Approval: Q3 2026 to Q1 2027 Developer: Boehringer Ingelheim Classification: Dual Agonist (Glucagon/GLP-1 receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials (SYNCHRONIZE program) Regulatory Status: FDA Breakthrough Therapy designation for MASH Retatrutide emerged from Eli Lillys research into multi-receptor agonism
Better yet, wait 6-8 weeks if you are experiencing fatigue or significant GI symptoms at your current dose
Lotte Bjerre Knudsen (45:38): Yeah, there is another hormone that's also in phase three clinical development, right
